Oncology

#Cancer research #Macomics #Macrophages #Omics #Oncology #Tumour microenvironment (TME) #Turning Science into Business

Turning science into business: Exploiting macrophage biology

DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs). What role… Read More

#Cancer Research #Exclusive Content

Cancer research lab
#American Society of Clinical Oncology #ASCO #Cancer research #Oncology #Phase II trial #The Institute of Cancer Research #The Royal Marsden NHS Foundation Trust

New drug combination twice as effective for some ovarian cancer patients

A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study. Researchers hope these results, which were presented at the 2023 American Society of Clinical… Read More

#Cancer Research #News

Non-small cell lung cancer
#American Society of Clinical Oncology #ASCO #AstraZeneca #Cancer research #Lung cancer #Oncology #Phase III trial

Lung cancer pill reduced risk of death by more than half

Positive results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The trial assessed osimertinib as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor… Read More

#Cancer Research #News #Trending News

#Cancer research #Cancer Research Month #Immuno-oncology #Oncology #Solid tumours

New podcast episode: DDW Highlights, 5 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With National Cancer Research Month coming to an end in May and the American Society… Read More

#News

#Cancer research #Cancer Research Month #Immuno-oncology #Oncology #Solid tumours

This week in drug discovery (29 May – 2 June)

News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer. With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another… Read More

#News

Male patient with doctor
#AstraZeneca #FDA #Merck #Oncology #Phase III trial #Prostate cancer

FDA extends US approval for olaparib in prostate cancer

Lynparza (olaparib) has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). The PARP inhibitor, developed by AstraZeneca and Merck (MSD), is approved in combination with abiraterone and prednisone or prednisolone. Read More

#News #Regulatory

#Cancer research #Collaboration #Data security #Flatiron Health #Lifebit #Oncology #Partnership #Real world data

Partnership hopes to accelerate cancer data research

Lifebit and Flatiron Health have announced a multi-year strategic partnership with the aim of improving scientific discoveries by learning from the experience of  cancer patients. Health data generated by hospitals, healthcare providers, research organisations and clinical trials hold the potential to advance research and innovation, improve… Read More

#Business & Investment #News

Presentation
#ASCO #Cancer research #Events #Oncology #Phase I trial #Syros Pharmaceuticals

Syros to present new clinical data at ASCO 2023

Biopharmaceutical company Syros Pharmaceuticals has announced new clinical data from the Phase I/Ib clinical trial evaluating SY-5609 in patients with relapsed/refractory pancreatic ductal adenocarcinoma (PDAC), HR+ breast cancer and other solid tumours. The data will be presented in two posters at the 2023 American Society for… Read More

#Cancer Research #News

T cells attacking cancer
#Bispecific therapeutics #Case study #Cytokines #Immunomodulators #Oncology #T cell activation #The Jackson Laboratory

Case Study: Unlock the potential of bispecific T cell engagers

Discover the groundbreaking findings from a study on bispecific T cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. Read More

#News

#Bispecific therapeutics #Case study #Cytokines #Immunomodulators #Oncology #T cell activation

Unlocking the potential of bispecific T-cell engagers: Efficacy and safety insights revealed

Discover the groundbreaking findings from a study on bispecific T-cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. What… Read More

#Resources

Monoclonal antibodies
#Aulos Bioscience #Cancer research #Immuno-oncology #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

AI-designed monoclonal antibody ‘redirects’ the immune system

Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The data indicate that AU-007 is well tolerated in patients with unresectable locally advanced or metastatic cancer and there are early signs of anti-tumour activity. Read More

#Cancer Research #Editor's Choice #News

#Cancer immunotherapy #Cancer research #Cancer Research Month #Diagnostics #Immunotherapy #Oncology #Precision medicine

National Cancer Research Month: Celebrating drug discovery innovation

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #European Commission #European Medicines Agency #Janssen #Myeloma #Oncology #Phase III trial

Janssen seeks EU approval of new indication for CAR-T therapy

The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed and lenalidomide-refractory multiple myeloma. The application is supported by data from the Phase III CARTITUDE-4 study,… Read More

#News #Regulatory

Seed fund
#BioInnovation Institute #Denmark #Immunotherapy #InProTher #Investment #Oncology #Seed funding #Start-ups

Danish immunotherapy start-up raises €6M seed funding

Danish start-up InProTher has raised €6 million seed funding from private investors, with participation from the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumours, into clinical development. Incubated at… Read More

#Business & Investment #News #Start-up Zone

#Antibodies #Antibody drug conjugate (ADC) #Apexigen #Mergers and acquisitions #Oncology #Pyxis Oncology

Pyxis Oncology to acquire antibody therapeutics company Apexigen

Pyxis Oncology has announced a definitive agreement by which it will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share,… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Funding #Investment #Medicinal chemistry #Neurology #Oncology #PharmEnable

$7.5M investment to target cancer and neurological diseases

PharmEnable has closed a pre-series A investment round of $7.5 million to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi Tanabe Pharma Group. Read More

#Business & Investment #News